Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It’s prescribed to treat autoimmune conditions. TNF is a protein that plays a key role in inflammation. In ...

It is the ninth Humira biosimilar approved by the FDA and the fourth to receive interchangeability status. The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the ...

The prescribed dosage for Humira (adalimumab) may vary depending on a person’s individual treatment plan. Other factors, including specific diagnosis, body weight, and medical history ...

Humira (adalimumab) is a prescription drug that’s used to treat certain conditions, such as rheumatoid arthritis. Humira can cause side effects that range from mild to serious. Examples include ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

Cantor Fitzgerald analyst Carter Gould initiated coverage of AbbVie (ABBV) with an Overweight rating and $210 price target AbbVie offers a ...

AbbVie generated $56 billion in revenue, achieving an operating profit of $12 billion and a net income of $4.3 billion, ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

Total Net Revenues: Over $13.3 billion, $550 million ahead of expectations. Ex-Humira Platform Sales Growth: More than 21% increase. Immunology Revenues: Over $6.2 billion, exceeding expectations.